

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. cancelled
2. cancelled
3. (original) A nucleic acid construct comprising a SIV-1 *gag* gene having the coding sequence of the *gag* gene set forth in Figure 3.
4. cancelled
5. (currently amended) A vector comprising the nucleic acid construct of Claim ~~1, 2, 3 or 4~~.
6. (currently amended) A transformed host cell comprising the nucleic acid construct of Claim ~~1, 2, 3 or 4~~.
7. (original) A transformed host cell of Claim 6 wherein said cell is a eukaryote.
8. (original) The host cell of Claim 7 wherein said cell is a human cell.
9. (original) A transformed host cell of Claim 6 wherein said cell is a prokaryote.
10. (original) The host cell of Claim 9 wherein said cell is E. coli.

11. (currently amended) A pharmaceutical composition comprising the nucleic acid construct of Claim ~~1, 2, 3 or 4~~ and a pharmaceutically acceptable carrier.

12. (original) A method for inducing antibodies in a mammal comprising administering to a mammal a composition of claim 11, wherein said nucleic acid construct is present in an amount which is effective to induce said antibodies in said mammal.

13. (original) A method for inducing cytotoxic T lymphocytes in a mammal comprising administering to a mammal a composition of claim 11, wherein said nucleic acid construct is present in an amount which is effective to induce cytotoxic T lymphocytes in said mammal.

Claims 14-31 cancelled

32. (original) A nucleic acid construct comprising a SIV-1 *env* gene having the coding sequence of the *env* gene set forth in Figure 16.

33. (original) A vector comprising the nucleic acid construct of claim 32.

34. (original) A transformed host cell comprising the nucleic acid construct of claim 32.

35. (original) A pharmaceutical composition comprising the nucleic acid construct of claim 32 and a pharmaceutically acceptable carrier.